ENvue Medical Issues Shareholder Letter, Outlook for 2026
ENvue Medical issued the following stockholder letter and corporate update: "2025 was a transformative year for ENvue Medical. Today, our Company is a commercially active medtech business trading on the Nasdaq Capital Market under the ticker "FEED." ENvue's mission is to improve patient safety and clinical workflow through proprietary technologies that deliver real-time guidance, intelligent navigation, and non-invasive therapeutic solutions... Our ENvue Navigation Platform is now commercially deployed across 39 U.S. hospitals, generating recurring revenue and becoming embedded in the daily workflows of clinicians who rely on it. We also continue to advance our Acoustic Therapeutic Platform through PainShield and UroShield, preserving valuable technology, commercial relationships and future optionality for stockholders... We believe we took the necessary steps in 2025 to build our foundation for the next phase of growth... 2026 Priorities 1. Accelerate ENvue Navigation Platform Adoption... 2. Advance Regulatory Milestones... 3. Scale At-Home and Non-Acute Enteral Solutions... In conclusion, we believe ENvue Medical is positioned in 2026 to become a stronger company with clearer focus, expanding commercial traction, two proprietary technology platforms, and a disciplined strategy for growth. Our navigation platform addresses a meaningful clinical need in a large market; our acoustic platform adds diversification and strategic optionality, and our team remains focused on execution."